The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid rising US trade scrutiny on pharmaceutical imports, the head of Swiss industry body Interpharma warned that Washington could open a trade investigation into Switzerland's pharma sector, mirroring a probe launched against Germany last week. He noted the industry faces new regulatory risks that could affect its crucial exports to the US market.
The development follows a similar US investigation into Germany, focusing on pricing and market access. Swiss giants Novartis (NVS) and Roche (RHHBY) have significant exposure to the US. Per market data, NVS closed at $155.12 on June 25, while RHHBY closed at $51.94, with narrow trading ranges.
Sign in to access this content
Sign InInvestors are watching for any official US statements that could define the scope of the probe. NVS traded between $155.85 and $153.42 on June 25, while RHHBY ranged $52.01–$51.16. Any advancement in the investigation could pressure pharma stocks, especially with no near-term positive catalysts on the horizon.